3/24
06:20 pm
nrxp
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files 2025 Form 10-K And Highlights Operational Progress [TheStreet.com]
High
Report
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files 2025 Form 10-K And Highlights Operational Progress [TheStreet.com]
3/24
03:21 pm
nrxp
NRX Pharmaceuticals Inc (NRXP) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Low
Report
NRX Pharmaceuticals Inc (NRXP) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
3/24
03:02 pm
nrxp
NRx Pharmaceuticals (NRXP) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $34.00 price target on the stock.
Low
Report
NRx Pharmaceuticals (NRXP) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $34.00 price target on the stock.
3/24
12:21 pm
nrxp
NRx Pharmaceuticals (NRXP) had its "buy" rating reaffirmed by BTIG Research. They now have a $25.00 price target on the stock.
Medium
Report
NRx Pharmaceuticals (NRXP) had its "buy" rating reaffirmed by BTIG Research. They now have a $25.00 price target on the stock.
3/24
10:42 am
nrxp
NRx Pharmaceuticals, Inc. (NRXP) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
NRx Pharmaceuticals, Inc. (NRXP) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/24
07:16 am
nrxp
NRx Pharmaceuticals GAAP EPS of -$1.34, revenue of $1.23M [Seeking Alpha]
High
Report
NRx Pharmaceuticals GAAP EPS of -$1.34, revenue of $1.23M [Seeking Alpha]
3/24
07:00 am
nrxp
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress
High
Report
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress
3/24
05:25 am
nrxp
NRx Pharmaceuticals Wraps Virtual Annual Meeting, Eyes Pivotal 2025 Earnings Call Ahead [Yahoo! Finance]
High
Report
NRx Pharmaceuticals Wraps Virtual Annual Meeting, Eyes Pivotal 2025 Earnings Call Ahead [Yahoo! Finance]
3/23
08:49 pm
nrxp
NRx Pharmaceuticals, Inc. (NRXP) Surpasses Q4 Earnings Estimates [Yahoo! Finance]
High
Report
NRx Pharmaceuticals, Inc. (NRXP) Surpasses Q4 Earnings Estimates [Yahoo! Finance]
3/23
11:48 am
nrxp
NRx Pharmaceuticals, Inc. (NRXP) Shareholder/Analyst Call Prepared Remarks Transcript [Seeking Alpha]
Low
Report
NRx Pharmaceuticals, Inc. (NRXP) Shareholder/Analyst Call Prepared Remarks Transcript [Seeking Alpha]
3/19
07:00 am
nrxp
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026
Low
Report
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026
3/17
07:12 am
nrxp
Yahoo Finance [Yahoo! Finance]
Medium
Report
Yahoo Finance [Yahoo! Finance]
3/17
07:00 am
nrxp
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx’s Preservative-Free Ketamine Application
Medium
Report
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx’s Preservative-Free Ketamine Application
3/16
03:21 pm
nrxp
NRx Pharmaceuticals (NRXP) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $34.00 price target on the stock.
Low
Report
NRx Pharmaceuticals (NRXP) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $34.00 price target on the stock.
3/16
07:08 am
nrxp
NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting [Yahoo! Finance]
Medium
Report
NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting [Yahoo! Finance]
3/16
07:00 am
nrxp
NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting
High
Report
NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting
3/14
08:12 pm
nrxp
New to The Street Episode #737 Airs on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM EST [Yahoo! Finance]
High
Report
New to The Street Episode #737 Airs on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM EST [Yahoo! Finance]
3/9
02:46 pm
nrxp
NRx Pharmaceuticals (NRXP) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $34.00 price target on the stock.
Low
Report
NRx Pharmaceuticals (NRXP) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $34.00 price target on the stock.
3/9
07:03 am
nrxp
HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD [Yahoo! Finance]
Low
Report
HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD [Yahoo! Finance]
3/9
07:00 am
nrxp
HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD
Low
Report
HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD
3/4
05:51 am
nrxp
NRx Pharmaceuticals (NRXP) was upgraded by Zacks Research from "strong sell" to "hold".
Low
Report
NRx Pharmaceuticals (NRXP) was upgraded by Zacks Research from "strong sell" to "hold".
3/3
11:46 am
nrxp
NRx Pharmaceuticals (NRXP) had its price target raised by HC Wainwright from $40.00 to $45.00. They now have a "buy" rating on the stock.
Low
Report
NRx Pharmaceuticals (NRXP) had its price target raised by HC Wainwright from $40.00 to $45.00. They now have a "buy" rating on the stock.
3/2
07:13 am
nrxp
NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer [Yahoo! Finance]
Low
Report
NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer [Yahoo! Finance]
3/2
07:00 am
nrxp
NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer
Low
Report
NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer
2/18
12:22 pm
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $25.00 price target on the stock.
Medium
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $25.00 price target on the stock.